AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 102 min read$TMO

CASPER MARC N sold $161K of TMO

CASPER MARC N (Chairman & CEO) sold 275 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $586.10 ($577.37–$593.32, $0.16M total) across 15 trades on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CASPER MARC N
Published Aug 10, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The newest information is the specific open-market sale details: 275 shares sold across 15 trades at a weighted average price of $586.1038, totaling $161,178.54, with holdings after the sale of 123,925 shares.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a fundamental repricing.

03

What to watch

The filing does not indicate intent beyond the plan; without additional context (e.g., multiple consecutive sales, buybacks, or earnings proximity), the signal is weak.

Relevance 3/10Novelty 5/10Timing: Filed after-hours on 2026-08-10, disclosing trades executed 2026-08-07.

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, reported by its Chairman & CEO.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher CEO/C chairman Casper Marc N sold $161,178 of TMO shares via an open-market sale under a 10b5-1 plan on 2026-08-07.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction, but it is explicitly tied to a pre-arranged 10b5-1 plan and the dollar amount is small relative to a mega-cap, reducing signal strength.

Market effects

Sector

No clear sector read-through; this is company-specific insider activity without operational or regulatory linkage.

Regional

Minimal, as the disclosure is unlikely to move broader US healthcare/life-science tools sentiment.

Global

Limited, since the event is a routine insider sale at a US-listed large-cap.

Counterpoint

What could challenge this read

Even 10b5-1 sales can coincide with periods of elevated valuation or personal liquidity needs, so traders may still fade near-term strength if flows look persistent.

Key entities

  • issuer
    THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    CASPER MARC N

    Chairman & CEO who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TMO insider trading history →

Related articles

OCT 6
$AXPMed

JPMorgan reveals stocks worth buying in October 2026

JPMorgan added five stocks to its Overweight list, highlighting American Express (AXP) as a Value pick, Thermo Fisher (TMO) and Liberty Energy (LBRT) as Growth picks. AXP is down 18-19% YTD but JPMorgan sees steady profits and share buybacks. TMO is up 25% in 3 months, with growth driven by partnerships and AI-powered lab machines. LBRT is up 52% in 12 months, benefiting from AI data center power demands.

finance.yahoo.com2 min
OCT 6
$QNTMMed

Quantum BioPharma Taps Thermo Fisher for Lucid-MS Phase 2 Trial in Multiple Sclerosis

Quantum BioPharma (QNTM) has partnered with Thermo Fisher Scientific to begin Phase 2 trials for Lucid-MS, a treatment for progressive multiple sclerosis. The FDA has cleared the trial, which will assess efficacy, safety, and tolerability. Thermo Fisher will provide clinical research services. Success could offer a new treatment option for MS, a condition with limited therapies. Quantum owns 19.84% of Unbuzzd Wellness and receives royalties from it.

citybuzz.co2 min
OCT 6
$QNTMMedAI 8/10

Quantum BioPharma Advances Multiple Sclerosis Trial with Thermo Fisher Partnership

Quantum BioPharma (QNTM) partnered with Thermo Fisher Scientific to start a Phase 2 trial for Lucid-MS, a treatment for progressive multiple sclerosis. The trial, cleared by the FDA, will assess efficacy, safety, and tolerability. Lucid-MS targets myelin degradation, differing from existing therapies. Quantum owns 19.84% of Unbuzzd Wellness, with royalty agreements in place.

citybuzz.co2 min
OCT 6
$QNTMMed

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

Quantum BioPharma (QNTM) has signed a contract with Thermo Fisher Scientific to implement its Phase 2 clinical trial for Lucid-MS, a treatment for multiple sclerosis. The trial will evaluate the drug's efficacy, safety, and tolerability. Quantum BioPharma received FDA clearance to proceed with the study. The multiple sclerosis market is projected to exceed $38 billion by 2030, according to Grand View Research.

globenewswire.com2 min